FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:524-526 August 12, 1999 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Aupérin, A. PubMed Citation

Small-cell lung cancer, the type of lung cancer most strongly associated with tobacco exposure, accounts for 20 to 25 percent of all cases of lung cancer (approximately 45,000 new cases per year in the United States). The majority of patients are treated with combination chemotherapy (etoposide and cisplatin) for four to six months, with or without concurrent thoracic irradiation. The median survival for patients who are not treated is only 6 to 12 weeks, whereas for patients treated with combination chemotherapy, the median survival is 10 to 12 months. For patients with extensive disease (disease extending beyond one hemithorax or . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Samson, D. J., Seidenfeld, J., Simon, G. R., Turrisi, A. T. III, Bonnell, C., Ziegler, K. M., Aronson, N. (2007). Evidence for Management of Small Cell Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition). Chest 132: 314S-323S [Abstract] [Full Text]  
• Osterlind, K. (2001). Chemotherapy in small cell lung cancer. Eur Respir J 18: 1026-1043 [Abstract] [Full Text]